---
schema_version: "secwatch.filing_event.v1"
accession: "0001100682-26-000115"
form_type: "8-K"
ticker: "CRL"
cik: "0001100682"
company_name: "CHARLES RIVER LABORATORIES INTERNATIONAL, INC."
filed_at: "2026-08-05T11:15:21+00:00"
generated_at: "2026-08-05T11:20:15.559314+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Charles River Q2: revenue $1.00B, GAAP loss $(0.03), non-GAAP EPS $3.02; guidance raised

## Summary
- Revenue $1.00B, down 2.7% YoY; organic revenue +0.1%, first positive since Q3 2023.
- GAAP net loss $(1.5)M ($(0.03)/diluted share) vs net income $52.3M ($1.06) in Q2 2025; loss driven by $63.7M divestiture loss.
- Non-GAAP EPS $3.02, down 3.2% from $3.12; non-GAAP operating margin 20.5% vs 22.1% YoY.
- Raises 2026 guidance: organic revenue growth now 0.0%-1.0% (prior -1.5% to -0.5%); non-GAAP EPS $11.15-$11.45 (prior $10.80-$11.30).
- Repurchased $100M of stock in Q2 at avg $174/share; $700M remaining under $1B authorization.

## SEC filing metadata
- accession: 0001100682-26-000115
- form_type: 8-K
- ticker: CRL
- cik: 0001100682
- company_name: CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
- filed_at: 2026-08-05T11:15:21+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1100682/000110068226000115/0001100682-26-000115-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1100682/000110068226000115/crl-20260805.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001100682-26-000115
- JSON: https://secwatch.observer/filing/0001100682-26-000115.json
- Plain text: https://secwatch.observer/filing/0001100682-26-000115.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.